These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 32321673)

  • 41. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
    Garnick MB; Mottet N
    BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
    Penson DF; Armstrong AJ; Concepcion R; Agarwal N; Olsson C; Karsh L; Dunshee C; Wang F; Wu K; Krivoshik A; Phung D; Higano CS
    J Clin Oncol; 2016 Jun; 34(18):2098-106. PubMed ID: 26811535
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer.
    Yu EY; Ellard SL; Hotte SJ; Gingerich JR; Joshua AM; Gleave ME; Chi KN
    Invest New Drugs; 2018 Apr; 36(2):278-287. PubMed ID: 29250742
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutic Effect of Ethinylestradiol in Castration-resistant Prostate Cancer.
    Nakano T; Kadono Y; Iwamoto H; Yaegashi H; Iijima M; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Mizokami A
    Anticancer Res; 2020 Apr; 40(4):2291-2296. PubMed ID: 32234928
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer.
    Emmenegger U; Booth CM; Berry S; Sridhar SS; Winquist E; Bandali N; Chow A; Lee C; Xu P; Man S; Kerbel RS; Ko YJ
    Oncologist; 2015 Dec; 20(12):1351-2. PubMed ID: 26542984
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer.
    Dorff TB; Tsao-Wei DD; Groshen S; Boswell W; Goldkorn A; Xiong S; Quinn DI; Pinski JK
    Clin Genitourin Cancer; 2013 Dec; 11(4):416-22. PubMed ID: 24099865
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study.
    Schweizer MT; Wang H; Luber B; Nadal R; Spitz A; Rosen DM; Cao H; Antonarakis ES; Eisenberger MA; Carducci MA; Paller C; Denmeade SR
    Prostate; 2016 Sep; 76(13):1218-26. PubMed ID: 27338150
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ; Shen T; Halabi S; Kemeny G; Bitting RL; Kartcheske P; Embree E; Morris K; Winters C; Jaffe T; Fleming M; George DJ
    Clin Genitourin Cancer; 2013 Dec; 11(4):397-406. PubMed ID: 23830964
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enzalutamide (Xtandi) for patients with metastatic, resistant prostate cancer.
    Bennett LL; Ingason A
    Ann Pharmacother; 2014 Apr; 48(4):530-7. PubMed ID: 24458946
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of Prior Local Treatment and Prostate-Specific Antigen Kinetics during Androgen-Deprivation Therapy on the Survival of Castration-Resistant Prostate Cancer.
    Hah YS; Lee JS; Rha KH; Hong SJ; Chung BH; Koo KC
    Sci Rep; 2019 Aug; 9(1):11899. PubMed ID: 31417160
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving
    Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A
    J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC).
    Barata P; Cooney M; Tyler A; Wright J; Dreicer R; Garcia JA
    Invest New Drugs; 2018 Jun; 36(3):451-457. PubMed ID: 29476383
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serum prostate specific antigen, sex hormone binding globulin and free androgen index as markers of pubertal development in boys.
    Kim MR; Gupta MK; Travers SH; Rogers DG; Van Lente F; Faiman C
    Clin Endocrinol (Oxf); 1999 Feb; 50(2):203-10. PubMed ID: 10396363
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase IIA clinical trial to test the efficacy and safety of Toremifene in men with high-grade prostatic intraepithelial neoplasia.
    Steiner MS; Pound CR
    Clin Prostate Cancer; 2003 Jun; 2(1):24-31. PubMed ID: 15046680
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer.
    Kim CS; Choi YD; Lee SE; Lee HM; Ueda T; Yonese J; Fukagai T; Chiong E; Lau W; Abhyankar S; Theeuwes A; Tombal B; Beer TM; Kimura G
    Medicine (Baltimore); 2017 Jul; 96(27):e7223. PubMed ID: 28682871
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase I safety and pharmacodynamic of inecalcitol, a novel VDR agonist with docetaxel in metastatic castration-resistant prostate cancer patients.
    Medioni J; Deplanque G; Ferrero JM; Maurina T; Rodier JM; Raymond E; Allyon J; Maruani G; Houillier P; Mackenzie S; Renaux S; Dufour-Lamartinie JF; Elaidi R; Lerest C; Oudard S
    Clin Cancer Res; 2014 Sep; 20(17):4471-7. PubMed ID: 25013124
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study.
    Stein CA; Levin R; Given R; Higano CS; Nemeth P; Bosch B; Chapas-Reed J; Dreicer R
    Urol Oncol; 2018 Feb; 36(2):81.e9-81.e16. PubMed ID: 29150328
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Enzalutamide-a novel androgen receptor inhibitor that provides treatment options for patients with castration-resistant prostate cancer].
    Maeda H; Saito A
    Gan To Kagaku Ryoho; 2014 Jul; 41(7):805-10. PubMed ID: 25131864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.